<DOC>
	<DOCNO>NCT01301183</DOCNO>
	<brief_summary>Teenage girl anorexia nervosa ( AN ) risk low bone density low rate bone accrual , raise concern regard acquisition peak bone mass , important determinant future bone health fracture risk . Important factor contribute low bone density AN include low level estrogen insulin like growth factor-1 ( IGF-1 ) . While estrogen important prevent bone loss , IGF-1 important optimize bone formation . We show previous study replacement estrogen effective increase bone density teenage girls AN ; however , increase bone density remain low see normal-weight control duration , residual deficit persist . Importantly , impact administer replacement dose IGF-1 estrogen replacement study teenager AN . This study examine impact administer recombinant human ( rh ) insulin like growth factor-1 ( rhIGF-1 ) estrogen ( mimic pubertal level hormone ) versus administration estrogen alone bone metabolism adolescent girl anorexia nervosa ( AN ) . One aim proposal investigate whether co-administration insulin like growth factor-1 ( rhIGF-1 ) physiologic estradiol replacement adolescent girl AN increase BMD ( bone mineral density ) estrogen monotherapy , whether bone mass approach see healthy adolescent girl . An additional aim determine whether co-administration rhIGF-1 estradiol mimic normal pubertal milieu stimulate bone formation IGF-1 mediate anabolic effect , increase bone density great extent estrogen monotherapy , improve bone mass accrual approach healthy control . The impact rhIGF-1 +estradiol versus estradiol alone bone microarchitecture also assess .</brief_summary>
	<brief_title>Effects Anorexia Nervosa Peak Bone Mass</brief_title>
	<detailed_description>Given increase prevalence AN , profound consequence bone health , lack optimal treatment intervention , study provide critical data need identify optimal treatment strategy severe co-morbid disease use state- of- the- art endpoint BMD , bone microarchitecture strength . Although low IGF-1 hypogonadism associate increase skeletal fragility AN , mechanisms factor interact incompletely understood . Specifically , increase skeletal fragility associate AN poorly reflect DXA-derived BMD . Furthermore , magnitude mechanism IGF-1 deficiency hypogonadism influence bone microarchitecture define . The grow incidence eat disorder adolescent girl long-term effect skeletal health provide strong rationale study provide good understand issue evaluation rational therapeutic approach . The study describe proposal utilize cross-sectional RCT approach achieve goal . Additionally , utilization sophisticate technique high resolution peripheral QCT ( HR-pQCT ) improve understand relationship IGF-1 , gonadal steroid bone quality aid development effective therapy treatment skeletal fragility Anorexia Nervosa .</detailed_description>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>AN : Age : 1422 year old Bone age ( BA ) : ≥14 year Should meet DSM IV criteria AN Subjects MGH evaluate coinvestigator Dr. David Herzog , Director Harris Center Eating Disorders , MGH , Dr. Debra Katzman , coinvestigator , Hospital Sick Children , Toronto direct Eating Disorders Program , respectively , enrollment . Controls : Healthy adolescent girl 1422 year BA ≥14 year BMI 10th90th percentile age Regular menstrual period every 2835 day subject ≥ 2 year postmenarche . Diseases know affect bone metabolism include untreated thyroid disease , Cushing 's syndrome , diabetes , pituitary disease , renal failure prior bone fracture within six month study . Medications know affect bone metabolism , include gonadal steroid , within three month . Evidence suicidality , psychosis , substance abuse . Premature ovarian failure , demonstrate elevated FSH . Abnormal TSH . Hematocrit &lt; 30 % , Potassium &lt; 3.0 mmol/L , Glucose &lt; 50 mg/dl Pregnancy History malignancy Contraindications estrogen therapy ( girls AN )</criteria>
	<gender>Female</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Anorexia Nervosa</keyword>
	<keyword>Estrogen</keyword>
	<keyword>Teenagers</keyword>
	<keyword>IGF-1</keyword>
</DOC>